AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02875561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 Laser Ablation
Description: To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
Study NCT02836327 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging
Study NCT02401958 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: 17 volunteers with RA and 17 without the disease, with a mean age of 54.7 + 6.63 underwent a resistance exercise session with a set of 12 repetitions at 50% of one repetition maximum (1RM ) and a set of 8 repetitions at 75% of 1RM. The exercises performed were: knee extension, knee flexion, hip abduction and hip adduction. Blood samples were obtained 30 minutes before, 5 minutes before, immediately after, 1 hour, 2 hours and 24 hours after the exercise session.
Study NCT02401958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: 17 volunteers with RA and 17 without the disease, with a mean age of 54.7 + 6.63 underwent a resistance exercise session with a set of 12 repetitions at 50% of one repetition maximum (1RM ) and a set of 8 repetitions at 75% of 1RM. The exercises performed were: knee extension, knee flexion, hip abduction and hip adduction. Blood samples were obtained 30 minutes before, 5 minutes before, immediately after, 1 hour, 2 hours and 24 hours after the exercise session.
Study NCT01168674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziprasidone
Description: Ziprasidone will be administered as a pill. The once-daily total daily dose will be 80-160 mg/d of ziprasidone. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
Study NCT01168674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: The once-daily total daily dose will be 80-160 mg/d of the sugar pill. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
Study NCT03124628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flywheel resistance exercise
Description: Flywheel resistance exercise, originally designed to maintain function, size and quality of skeletal muscle during spaceflight, employs iso-inertial technology rather than gravity dependent weights, which allows for coupled accommodated concentric and eccentric muscle actions, and brief episodes of eccentric overload.
Study NCT03124628 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight-stack resistance exercise
Description: Conventional weight-stack resistance exercise
Study NCT04029558 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination of Plant Extracts (BSL_EP025)
Description: Each participant will consume 2 capsules daily at lunch for 8 weeks.
Study NCT04029558 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will consume 2 capsules daily at lunch for 8 weeks.
Study NCT00469781 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 2. Xibrom (Bromfenac)
Description: Group 1 and 2: 1 drop(Instill one drop in the eye that was operated on twice daily)3 days prior to surgery and 4 doses during dilation immediately before the procedure. Use for 4 weeks after surgery.
Study NCT00469781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1. Pred Forte
Description: Group 1 Instill one drop in the eye that was operated on four times a day starting on day of surgery and use for four weeks.~Group 2 Instill one drop in the eye that was operated on twice a day starting on day of surgery and use for four weeks.
Study NCT01923428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722
Study NCT01923428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02076685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid
Description: dose adjustment according to the pharmacogenomic results
Study NCT04268953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricaprilin
Description: Tricaprilin formulated as AC-SD-03 mixed in 300mL water
Study NCT03253770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIMMAX2
Description: Digital cognitive aid or paper cognitive aid during the management of a cardiac arrest in the recovery room or in the delivery room.
Study NCT03989791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: absolute diet
Description: Patients in absolute diet group were fasted from any food with intravenous infusion of 5% glucose and sodium chloride instead in the first 24 hours. Then, the patients will be given soup for the next 24 hours if there was no delayed complication or discomfort during the fasting. Finally, they will gradually transit from soup to normal diet such as porridge, noodles and rice in the third 24 hours.
Study NCT03989791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: normal diet
Description: Patients in normal diet group were directly given normal diet such as porridge, noodles and rice as usual after polypectomy. Meanwhile, all the patients in two groups were given PPI for 3 days intravenously and restricted from vigorous exercise for 14 days.
Study NCT00589550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2b
Description: administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
Study NCT00589550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Study NCT00589550 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Study NCT00589550 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Study NCT00589550 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Study NCT00589550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Study NCT00589550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Study NCT00589550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT03684005 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MyPatientPal smartphone app
Description: All patients in this single-arm study will use a smartphone-based app, MyPatientPal, to enter symptoms and track medications related to their cancer treatment. No drugs will be administered for the purposes of this behavioral study.
Study NCT01023880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-18770
Description: CEP-18770 beginning at a dose of 1.5 mg/m2. Patients will receive I.V. administration on days 1, 8, 15 (up to 8 cycles of 28 days each). When the MTD is established, additional patients will be treated at the MTD.
Study NCT03514264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gutta Percha and AHPLUS cement (group A)
Description: First intervention: endodontic instrumentation and introduction of intact medication that will remain inside the tooth for 4 weeks.~Second intervention: removal of intracanal medication and canal filling with cement AHPLUS and guttapercha
Study NCT03514264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBS CIMMO cement (group B)
Description: Single intervention: endodontic instrumentation and obturation with cement PBS CIMMO
Study NCT03441113 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MMB
Description: Tablet(s) administered orally once daily
Study NCT03694015 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SUPR
Description: simple unplanned palliative radiotherapy-(either 8 Gy in 1 fraction or 20 Gy in 5 fractions), chosen pre-randomization at ROs or centres discretion
Study NCT03694015 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: VMAT
Description: volumetric modulated arc therapy--(either 8 Gy in 1 fraction or 20 Gy in 5 fractions), chosen pre-randomization at ROs or centres discretion
Study NCT02304328 — intervention group
Intervention type: OTHER
Intervention: Clinical assessment
Description: Patients will be clinically assessed whether they present clinical signs of brain herniation syndromes
Study NCT02406118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal total mesorectal excision
Description: Subjects will have their rectal cancer removed using a technique combining surgery through the anus and standard laparoscopy. Transanal visualization will be using endoscopy. At the end of the procedure, the rectum will be removed though the anus or ileostomy formation site, the bowel will be re-connected to the anus, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
Study NCT00579540 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flax Seed Oil
Description: Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
Study NCT00579540 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
Study NCT00579540 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soybean Oil
Description: Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
Study NCT03766893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine / Naloxone Oral Product
Description: To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly (buprenorphine/naloxone) basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.
Study NCT03766893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injectable naltrexone
Description: To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
Study NCT01187810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide
Description: 925 mg/m2 IV continuous infusion X 5 days for 6 cycles. Dose escalation will occur on a 3X3 basis.
Study NCT01187810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: dosing depending on age - will be administed intrathecally for all CNS negative subjects on day 0 and 15 of course 1, then on day 8 of each remaining cycle for CNS negative AML. For CNS positive ALL, NHL, and AML, will be administered alone on day 0 for and in combination with methotrexate and hydrocortisone on day 8, 15, 22 of cycle 1 and repeated on day 8 of each remaining cycle
Study NCT01187810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Dose depends on subject age - for CNS positive patients, will be given in combination with cytarabine and hydrocortisone on days 8, 15, and 22 during course 1. For courses 2-6, will be administered intrathecally on day 8 for CNS negative ALL and NHL. For patients who are CNS positive, it will be given in combination with cytarabine and hydrocortisone on day 8 of courses 2-6.
Study NCT02970786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 68Ga-NODAGA-E(c[RGDyK])2
Description: Following one injection of 68Ga-NODAGA-E(c\[RGDyK\])2 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
Study NCT00661713 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ
Study NCT02735707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No antiplatelet
Description: No antiplatelet agent or NSAID to be administered.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Description: Aspirin administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: P2Y12 inhibitor
Description: Site-selected P2Y12 inhibitor:~* Clopidogrel: administered 75 mg once per day for 14 days or until hospital discharge, whichever occurs first.~* Prasugrel: If patient is aged less than 75 years and measured or estimated weight if 60kg or more, and initial loading dose of prasugrel 60 mg will be administered, followed by maintenance dose of 10 mg per day.~* Ticagrelor: administered enterally at 60mg twice daily for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No simvastatin
Description: No simvastatin intended to be active against COVID-19 is to be administered~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Simvastatin
Description: Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Eritoran
Description: Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apremilast
Description: Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Clinician-preferred mechanical ventilation strategy
Description: Clinician-preferred ventilation strategy, including mode of ventilation and all ventilatory parameters
Study NCT02735707 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Protocolised mechanical ventilation strategy
Description: Invasive mechanical ventilation strategy delivered as outlined in relevant protocol documents for this domain.
Study NCT02735707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No renin-angiotensin system inhibitor
Description: No RAS inhibitor (i.e. no ACEi or ARB) is to be administered up to the end of study day 10.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Angiotensin converting enzyme inhibitor
Description: Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Angiotensin Receptor Blockers
Description: Site-preferred ARB agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ARB + DMX-200
Description: Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first.~ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No cysteamine
Description: No cysteamine to be administered until the end of study day 10 or hospital discharge, whichever occurs first.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cysteamine
Description: Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first.~Note: this intervention is now closed.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fixed-duration dexamethasone
Description: 6 mg of IV or enteral dexamethasone will be administered daily for up to 10 days while in hospital.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Baloxavir Marboxil
Description: Baloxavir marboxil administered on days 1 and 4 post-randomisation.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Five-days oseltamivir + baloxavir marboxil
Description: Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ten-days oseltamivir + baloxavir marboxil
Description: Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
Study NCT00661713 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02735707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No endothelial modulator
Description: No endothelial modulator (imatinib or another tyrosine kinase inhibitor targeting the same pathway as imatinib) is to be administered.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib
Description: Enteral imatinib will be administered as a single 800mg loading dose (study day 1) followed by 400mg daily until study day 14 or discharge.
Study NCT02735707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Immune Modulator for Influenza
Description: No immune modulating agent intended to be active against influenza is to be administered.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tocilizumab
Description: Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. In children weighing less than 30kg, tocilizumab dose will be 12mg/kg.~Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Baricitinib
Description: Baricitinib will be administered at a dose that is determined by age and renal function, for up to 10 days or hospital discharge (whichever occurs first).
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nirmatrelvir/ritonavir
Description: Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Remdesivir
Description: Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
Study NCT02735707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nirmatrelvir/ritonavir + remdesivir
Description: Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days. Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
Study NCT04480333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: NA-831 - 0.10 mg/kg
Description: NA-831 in nanoparticle inhalation formulation
Study NCT04480333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- 0.10 mg/kg
Description: Placebo in nanoparticle inhalation formulation
Study NCT04480333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: NA-831 - 0.20 mg/kg
Description: NA-831 in nanoparticle inhalation formulation
Study NCT04480333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- 0.20 mg/kg
Description: Placebo in nanoparticle inhalation formulation
Study NCT04480333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: GS-5734 - 1.00 mg/kg
Description: GS-5734 in nanoparticle inhaled formulation
Study NCT04480333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- 1.00 mg/kg
Description: Placebo in nanoparticle inhalation formulation
Study NCT04480333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: GS-5734 - 2.00 mg/kg
Description: GS-5734 in nanoparticle inhaled formulation
Study NCT04480333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- 2.00 mg/kg
Description: Placebo in nanoparticle inhaled formulation